Andreas Gille

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/112882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein Aâ€I and cholesterol efflux capacity in acute myocardial infarction patients. British Journal of Clinical Pharmacology, 2021, 87, 2558-2571.	2.4	9
2	Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein Aâ€I [Human]) to Enhance Cholesterol Efflux Capacity. Journal of Clinical Pharmacology, 2019, 59, 427-436.	2.0	10
3	Pharmacokinetics and Safety of CSL112 (Apolipoprotein Aâ€I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function. Clinical Pharmacology in Drug Development, 2019, 8, 628-636.	1.6	13
4	CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 953-963.	2.4	54
5	Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nature Communications, 2017, 8, 15557.	12.8	321
6	CSL112 ENHANCES THE ABILITY OF SERUM TO EFFLUX CHOLESTEROL IN PATIENTS WITH MODERATE RENAL IMPAIRMENT. Journal of the American College of Cardiology, 2017, 69, 54.	2.8	0
7	Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112. Circulation Research, 2016, 119, 751-763.	4.5	85
8	Reconstituted highâ€density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component. Journal of Applied Toxicology, 2016, 36, 1038-1047.	2.8	15
9	Infusion of Reconstituted Highâ€Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Journal of the American Heart Association, 2015, 4, e002171.	3.7	89
10	Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience, 2015, 290, 126-137.	2.3	192
11	Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nature Medicine, 2015, 21, 173-177.	30.7	251
12	A multiple ascending dose study of CSL112, an infused formulation of ApoAâ€ I . Journal of Clinical Pharmacology, 2014, 54, 301-310.	2.0	74
13	Alignment-Annotator web server: rendering and annotating sequence alignments. Nucleic Acids Research, 2014, 42, W3-W6.	14.5	56
14	Sequence alignment visualization in HTML5 without Java. Bioinformatics, 2014, 30, 121-122.	4.1	233
15	CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2106-2114.	2.4	91
16	Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2202-2211.	2.4	106
17	GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes. Endocrinology, 2013, 154, 3552-3564.	2.8	436
18	Inhibitors of membranous adenylyl cyclases. Trends in Pharmacological Sciences, 2012, 33, 64-78.	8.7	90

ANDREAS GILLE

#	Article	IF	CITATIONS
19	Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. , 2012, 136, 1-7.		35
20	Structure–activity relationships for the interactions of 2′- and 3′-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases. Biochemical Pharmacology, 2011, 82, 358-370.	4.4	17
21	Structural Basis for the High-Affinity Inhibition of Mammalian Membranous Adenylyl Cyclase by 2′,3′- <i>O</i> -(<i>N</i> -Methylanthraniloyl)-Inosine 5′-Triphosphate. Molecular Pharmacology, 2011, 80, 87-96.	2.3	11
22	Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. Journal of Clinical Investigation, 2011, 121, 1163-1173.	8.2	221
23	An Autocrine Lactate Loop Mediates Insulin-Dependent Inhibition of Lipolysis through GPR81. Cell Metabolism, 2010, 11, 311-319.	16.2	291
24	Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in mice. Journal of Clinical Investigation, 2010, 120, 2910-2919.	8.2	173
25	Characterization of Mouse Heart Adenylyl Cyclase. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 1156-1165.	2.5	35
26	Molecular Analysis of the Interaction of Anthrax Adenylyl Cyclase Toxin, Edema Factor, with 2′(3′)- <i>O</i> -(<i>N</i> -(methyl)anthraniloyl)-Substituted Purine and Pyrimidine Nucleotides. Molecular Pharmacology, 2009, 75, 693-703.	2.3	36
27	Differential Inhibition of Various Adenylyl Cyclase Isoforms and Soluble Guanylyl Cyclase by 2′,3′- <i>O</i>	2.5	22
28	Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs. Biochemical Pharmacology, 2009, 78, 62-69.	4.4	20
29	Nicotinic Acid: Pharmacological Effects and Mechanisms of Action. Annual Review of Pharmacology and Toxicology, 2008, 48, 79-106.	9.4	263
30	Ca2+ signalling of kinins in cells expressing rat, mouse and human B1/B2-receptor. International Immunopharmacology, 2008, 8, 276-281.	3.8	34
31	Nicotinic Acid-Induced Flushing Is Mediated by Activation of Epidermal Langerhans Cells. Molecular Pharmacology, 2006, 70, 1844-1849.	2.3	194
32	Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors. Molecular Pharmacology, 2006, 70, 878-886.	2.3	51
33	Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5′-triphosphates, nucleoside 5′-[γ-thio]triphosphates and nucleoside 5′-[β,γ-imido]triphosphates. Biochemical Pharmacology 2005, 71, 89-97.	V,4.4	16
34	GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing. Journal of Clinical Investigation, 2005, 115, 3634-3640.	8.2	297
35	Structural Basis for the Inhibition of Mammalian Membrane Adenylyl Cyclase by 2 ′(3′)-O-(N-Methylanthraniloyl)-guanosine 5 ′-Triphosphate. Journal of Biological Chemistry, 2005, 280, 7253-7261	3.4	66
36	Differential Inhibition of Adenylyl Cyclase Isoforms and Soluble Guanylyl Cyclase by Purine and Pyrimidine Nucleotides. Journal of Biological Chemistry, 2004, 279, 19955-19969.	3.4	91

ANDREAS GILLE

#	Article	IF	CITATIONS
37	Xanthine nucleotide-specific G-protein a-subunits: a novel approach for the analysis of G-protein-mediated signal transduction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 141-150.	3.0	9
38	Low-affinity interactions of BODIPY-FL-GTP?S and BODIPY-FL-GppNHp with Gi- and Gs-proteins. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 368, 210-215.	3.0	17
39	MANT-substituted guanine nucleotides: A novel class of potent adenylyl cyclase inhibitors. Life Sciences, 2003, 74, 271-279.	4.3	5
40	Co-expression of the β2-adrenoceptor and dopamine D1-receptor with Gsα proteins in Sf9 insect cells: limitations in comparison with fusion proteins. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1613, 101-114.	2.6	19
41	2′(3′)-O-(N-Methylanthraniloyl)-substituted GTP Analogs: A Novel Class of Potent Competitive Adenylyl Cyclase Inhibitors. Journal of Biological Chemistry, 2003, 278, 12672-12679.	3.4	45
42	GDP Affinity and Order State of the Catalytic Site Are Critical for Function of Xanthine Nucleotide-selective GαsProteins. Journal of Biological Chemistry, 2003, 278, 7822-7828.	3.4	11
43	2â€~(3â€~)-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors Journal of Biological Chemistry, 2003, 278, 31456.	3.4	0
44	Distinct Interactions of GTP, UTP, and CTP with GsProteins. Journal of Biological Chemistry, 2002, 277, 34434-34442.	3.4	13
45	TGGE-STAR: Primer Design for Melting Analysis Using PCR Gradient Gel Electrophoresis. BioTechniques, 2002, 32, 264-268.	1.8	4
46	Bipolar clamping improves the sensitivity of mutation detection by temperature gradient gel electrophoresis. Electrophoresis, 1998, 19, 1347-1350.	2.4	13